Welcome to our dedicated page for Essa Pharma SEC filings (Ticker: EPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, shifting cash burn, and abrupt program terminations make ESSA Pharma’s SEC documents challenging to decode. If you’ve searched “ESSA Pharma SEC filings explained simply” or asked how to track masofaniten updates inside a terse 8-K, you know the struggle—and the stakes.
Stock Titan’s AI ends that friction. Our engine converts the 200-page “ESSA Pharma annual report 10-K simplified” into a plain-English brief, highlights cash-runway tables, and flags every risk-factor change. Looking for the latest “ESSA Pharma quarterly earnings report 10-Q filing”, or need instant alerts on “ESSA Pharma insider trading Form 4 transactions”? We pull each document directly from EDGAR, parse the science and the numbers, and surface what matters first.
Use the platform to:
- Follow “ESSA Pharma Form 4 insider transactions real-time” and spot buying or selling before clinical news breaks.
- Compare leadership incentives by scanning the “ESSA Pharma proxy statement executive compensation”.
- Read “ESSA Pharma 8-K material events explained” to understand why trials pause, pivot, or stop.
Whether you need an “ESSA Pharma earnings report filing analysis”, insight into dilution risk, or simply guidance on “understanding ESSA Pharma SEC documents with AI,” Stock Titan delivers comprehensive, real-time coverage and clarity you can trust.
ESSA Pharma Inc. filed a Post-Effective Amendment to its Form S-3 to withdraw and remove from registration any unissued and unsold securities previously registered for up to $200,000,000. This follows the completion of a business combination in which Xeno Acquisition Corp. acquired all outstanding common shares on October 9, 2025.
Shareholders received an initial cash distribution of $1.6910318 per share prior to closing and approximately $0.1242 per share at closing, plus one non-transferable CVR per share with the right to receive up to approximately $0.14 per CVR. The potential CVR pool totals up to $6.7 million, contingent on specified outcomes. As a result of the transaction, ESSA terminated all offerings under the registration and ended the effectiveness of the registration statement.
ESSA Pharma (EPIX) reported an insider transaction tied to its completed business combination. The company’s Chief Financial Officer disposed of 33,343 common shares on October 9, 2025, as all outstanding shares were acquired by Xeno Acquisition Corp. pursuant to the Business Combination Agreement.
Holders received approximately US$0.12 per share in cash plus one contingent value right (CVR) per share, which entitles the holder to receive up to approximately US$0.14 per CVR within specified periods after closing. Following the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma (EPIX) disclosed a Form 4 reflecting the completion of its sale on October 9, 2025. A reporting director disposed of 43,240 common shares, reducing beneficial ownership to 0 shares following the transaction.
Under the Business Combination Agreement among ESSA Pharma, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, all issued and outstanding common shares were acquired for
ESSA Pharma (EPIX) reported an insider Form 4 tied to its merger close. On October 9, 2025, all common shares were acquired by Xeno Acquisition Corp. under a Business Combination Agreement.
The reporting person disposed of 14,299 common shares, reducing beneficial ownership to zero. Holders received approximately
ESSA Pharma (EPIX) reported an insider transaction tied to its acquisition. On October 9, 2025, a director disposed of 30,002 common shares, reflecting the closing of a business combination in which all outstanding shares were acquired. Holders received approximately US$0.12 in cash per share plus one contingent value right (CVR) per share.
The CVR entitles the holder to receive up to approximately US$0.14 per CVR, payable within specified periods following the close. Following the transaction, the reporting person held 0 shares directly.
ESSA Pharma (EPIX) reported an insider transaction: President and CEO David Parkinson, also a director, disposed of 65,675 common shares on October 9, 2025. The transaction occurred in connection with a business combination under which the purchaser acquired all issued and outstanding common shares for approximately US$0.12 per share plus one CVR per share entitling holders to receive up to approximately US$0.14 per CVR.
Following the transaction, the filing lists 0 shares beneficially owned.
ESSA Pharma (EPIX) reported an insider transaction tied to its change of control. A director filed a Form 4 showing the disposition of 784,404 common shares on October 9, 2025, coinciding with the closing of a business combination.
According to the filing, Xeno Acquisition Corp. acquired all issued and outstanding ESSA common shares for approximately US$0.12 per share in cash plus one contingent value right (CVR) per share entitling holders to receive up to approximately US$0.14 per CVR within specified periods following closing.
ESSA Pharma (EPIX) director reports merger-related share disposition. A Form 4 shows the reporting person disposed of 2,881 common shares on 10/09/2025 in connection with a completed business combination. All issued and outstanding ESSA Pharma shares were acquired by Xeno Acquisition Corp. for approximately US$0.12 per share plus one contingent value right (CVR) per share.
Each CVR entitles its holder to receive up to approximately US$0.14 per CVR, payable within specified periods following closing. After the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma Inc. (EPIX) insiders affiliated with Biotechnology Value Fund entities reported share dispositions tied to the company’s merger. On
Per the terms, holders received
Nasdaq has submitted a Form 25 to remove the listing of ESSA Pharma Inc. The filing names the issuer as ESSA Pharma Inc. (symbol EPIX) with principal offices in Vancouver, British Columbia. The form cites compliance with the Exchange's procedures under the federal rules that govern delisting and voluntary withdrawal but does not state the reason, effective date, or indicate which specific rule provision was checked. No financial results, transactions, or timelines are included.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
